Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2025 | SRS versus WBRT in managing breast cancer brain metastases

Icro Meattini • 8 May 2025
ESMO Breast 2025
Breast Cancer

Icro Meattini, MD, University of Florence, Florence, Italy, discusses the current evidence supporting stereotactic radiosurgery (SRS) as the preferred treatment for brain metastases in breast cancer. SRS has shown effectiveness even in patients with multiple lesions and whole brain radiotherapy (WBRT) is now reserved for select cases. Patient selection for SRS should also be guided by disease biology, treatment history, comorbidities, and overall fitness, and that for most eligible patients, SRS should be the first-line radiotherapeutic option. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.

All content is owned by Magdalen Medical Publishing (MMP) and protected under international copyright laws. All rights reserved.

More from Icro Meattini

Early breast cancer: multimodal de-escalation strategies to reduce treatment burden safely
5:20
Early breast cancer: multimodal de-escalation strategies to reduce treatment burden safely
Icro Meattini • 10 Jul 2025
BRCA carrier status and radiation therapy in young patients with breast cancer
2:34
BRCA carrier status and radiation therapy in young patients with breast cancer
Icro Meattini • 30 May 2025
Moderate hypofractionation in high-risk breast cancer
3:07
Moderate hypofractionation in high-risk breast cancer
Icro Meattini • 30 May 2025
BRCA1 and BRCA2 carrier status: implications for breast cancer treatment
1:28
BRCA1 and BRCA2 carrier status: implications for breast cancer treatment
Icro Meattini • 30 May 2025

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals